A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Part of paid clinical trials in Los Angeles, California.

Sponsor
AstraZeneca
Study ID
NCT00378482
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 130 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.

Key Dates

Start date
Mar 5, 2007
Status verified
Aug 2024
Primary completion
Oct 27, 2023
Completion
Oct 27, 2023

Study Design

Enrollment
37 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Drug: CP-675,206 (Tremelimumab)

Primary Outcome Measure

Safety Endpoints: Serious Adverse Events to Tremelimumab. [ Time Frame: Following the first dose, until at least 90 days since the previous dose of tremelimumab or at least 28 days since any study-related procedures. Actual median study duration was 2.2 years. ]

Locations (5)

FacilityCityStateZIPSite coordinators
Research SiteLos AngelesCalifornia90024-
Research SiteTampaFlorida33612-
Research SiteAnn ArborMichigan48109-
Research SiteNew YorkNew York10016-
Research SiteHoustonTexas77030-

Find similar trials in Los Angeles, CA

By condition
Colorectal cancerMelanomaProstate cancerKidney cancer
By specialty
OncologyGI oncologySkin cancerDermatologyProstate oncologyMen's healthUrology
By research site
Research Site· Los Angeles, CAResearch Site· Tampa, FLResearch Site· Ann Arbor, MIResearch Site· New York, NYResearch Site· Houston, TX

Related Studies